cyclic heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-29 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Asia: United Arab Emirates (17), Saudi Arabia (13), Kuwait (7), South Korea (9), Hong Kong (8), China (5), Bahrain (4), Malaysia (3), Macau (3), Qatar (3), Singapore (2). Europe: United Kingdom (178), Spain (44), France (41), Germany (35), Italy (10), Netherlands (4), Ireland (4), Switzerland (4), Sweden (3), Austria (2), Belgium (2), Denmark (2), Luxembourg (1), Czech Republic (1). North America: United States (1,517), Canada (72). Oceania: Australia (5).
In 1800, France built Nautilus, a human-powered submarine designed by American Robert Fulton. They gave up on the experiment in 1804, as did the British, when they reconsidered Fulton's submarine design. In 1850, Wilhelm Bauer's Brandtaucher was built in Germany. It remains the oldest known surviving submarine in the world. In 1864, late in the American Civil War, the Confederate navy's H. L. Hunley became the first military submarine to sink an enemy vessel, the Union sloop-of-war USS Housatonic, using a gun-powder-filled keg on a spar as a torpedo charge. The Hunley also sank. The explosion's shock waves may have killed its crew instantly, preventing them from pumping the bilge or propelling the submarine. In 1866, Sub Marine Explorer was the first submarine to successfully dive, cruise underwater, and resurface under the crew's control. The design by German American Julius H. Kroehl (in German, Kröhl) incorporated elements that are still used in modern submarines. In 1866, Flach was built at the Chilean government's request by Karl Flach, a German engineer and immigrant. It was the fifth submarine built in the world and, along with a second submarine, was intended to defend the port of Valparaíso against attack by the Spanish Navy during the Chincha Islands War.
== Hazards == Radium is highly radioactive, as is its immediate decay product, radon gas. When ingested, 80% of the ingested radium leaves the body through the feces, while the other 20% goes into the bloodstream, mostly accumulating in the bones. This is because the body treats radium as calcium and deposits it in the bones, where radioactivity degrades marrow and can mutate bone cells. Exposure to radium, internal or external, can cause cancer and other disorders, because radium and radon emit alpha and gamma rays upon their decay, which kill and mutate cells. Radium is generally considered the most toxic of the radioactive elements. Some of the biological effects of radium include the first case of "radium-dermatitis", reported in 1900, two years after the element's discovery. The French physicist Antoine Becquerel carried a small ampoule of radium in his waistcoat pocket for six hours and reported that his skin became ulcerated. Pierre Curie attached a tube filled with radium to his arm for ten hours, which resulted in the appearance of a skin lesion, suggesting the use of radium to attack cancerous tissue as it had attacked healthy tissue. Handling of radium has been blamed for Marie Curie's death, due to aplastic anemia, though analysis of her levels of radium exposure done after her death find them within accepted safe levels and attribute her illness and death to her use of radiography. A significant amount of radium's danger comes from its daughter radon, which as a gas can enter the body far more readily than can its parent radium.
Sources: en.wikipedia.org
==== Aerobic ==== Aerobic exercise for fibromyalgia patients is the most investigated type of exercise. It includes activities such as walking, jogging, spinning, cycling, dancing and exercising in water, with walking being named as one of the best methods. A 2017 Cochrane summary concluded that aerobic exercise probably improves quality of life, slightly decreases pain and improves physical function and makes no difference in fatigue and stiffness. A 2019 meta-analysis showed that exercising aerobically can reduce autonomic dysfunction and increase heart rate variability. This happens when patients exercise at least twice a week, for 45–60 minutes at about 60%–80% of the maximum heart rate. Aerobic exercise also decreases anxiety and depression, and improves the quality of life. Exercising aerobically 2–3 times a week has been shown to alleviate pain.
For example, sodium o-phenylphenate-resistant strains are dealt with via formaldehyde fumigation, while imazalil-resistant strains are controlled through the use of pyrimethanil, a fungicide also approved for fighting strains resistant to other fungicides. As fungicide resistance increases globally, other measures of control are being considered, including that of biocontrol. Effective biocontrol agents include bacteria such as Bacillus subtilis, Pseudomonas cepacia, and Pseudomonas syringae as well as fungi such as Debaryomyces hansenii and Candida guilliermondii. In Clementines and Valencia oranges, Candida oleophila, Pichia anomala, and Candida famata have been shown to reduce disease. Despite the ability of various biocontrol agents to exhibit antagonistic activity, biocontrol has not been shown to provide complete control over P.digitatum, and is therefore commonly used in conjunction with another measure of control. Alternative measures of control include essential oils such as Syzygium aromaticum and Lippia javanica, ultraviolet light, gamma-irradiation, X-ray curing, vapour heat, and cell-penetrating anti-fungal peptides.
==== Mosque ==== Ibelin's parish church was converted into a mosque, to which a minaret was added during the Mamluk period in 1337. The minaret is still standing, although the mosque itself (the former Crusader church) was blown up by the IDF in 1950.
Sources: en.wikipedia.org
Additionally, francium superoxide (FrO2) is expected to have significant covalent character, unlike the other alkali metal superoxides, because of bonding contributions from the 6p electrons of francium.
=== European Union === The European Union permits a maximum thujone level of 35 mg/kg in alcoholic beverages where Artemisia species is a listed ingredient, and 10 mg/kg in other alcoholic beverages. Member countries regulate absinthe production within this framework. The sale of absinthe is permitted in all EU countries unless they further regulate it.
By August 1978, the Genentech scientists were able to synthesize human insulin, and in that same month, Swanson and colleagues negotiated a multimillion-dollar contract with Eli Lilly. The big company-small company relationship they developed became the eventual template for other biotechnology start ups. While there was still plenty of work to be done on the human insulin synthesis, the new stream of revenues and the significant amount of media coverage meant that Genentech could pursue other research projects. By 1979, Genentech had projects on interferons, animal growth hormones, hepatitis B vaccines, and the hormone thymosin. By 1980, Swanson decided that they should raise money by making Genentech public. This was due to a variety of factors. Genentech needed more money to continue its development, and Swanson believed that the public interest in the technology should be capitalized on. The initial public offering took place on October 14, 1980, and it was the largest IPO ever, at that moment in history, with Genentech raising 35 million dollars. A trip to Europe in September 1980 to raise interest from European investors before the IPO also served as his honeymoon. From here on, Swanson would focus on pursuing his vision of Genentech as a self sustainable biotechnology company, not a contract research operation. He believed that recombinant growth hormones had a large market in the United States, and that they would be key for Genentech's corporate evolution.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.